ASND - アセンディス・ファ―マ (Ascendis Pharma A/S) アセンディス・ファ―マ

 ASNDのチャート


 ASNDの企業情報

symbol ASND
会社名 Ascendis Pharma A/S (アセンディス・ファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH the Company has developed a pipeline of long-acting prodrug product candidates such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH) TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. It is also using its TransCon technology platform to develop TransCon Parathyroid Hormone (TransCon PTH) for hypoparathyroidism a rare endocrine disorder of calcium and phosphate metabolism.   アセンディス・ファ―マは、デンマ―クのバイオ医薬品会社。高価値の薬のプロドラッグ・バ―ジョンを開発。小児成長ホルモン欠損症、成人成長ホルモン欠損症、肺動脈高血圧症、糖尿病および眼科の治療のために、独自の「TransCon技術」を用いて、既存の薬物のバ―ジョンを改善した製品候補を生成する。   Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes on its TransCon technologies to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau on September 21, 2006 and is headquartered in Hellerup, Denmark.
本社所在地 Tuborg Boulevard 5 Hellerup DK-2900 DNK
代表者氏名 Michael Wolff Jensen マイケル・ウォルフ・イェンセン
代表者役職名 Chairman of the Board Senior Vice President General Counsel
電話番号
設立年月日 2006年
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 137人
url www.ascendispharma.com
nasdaq_url https://www.nasdaq.com/symbol/asnd
adr_tso 39488792
EBITDA EBITDA(百万ドル) -164.46230
終値(lastsale) 66.33
時価総額(marketcap) 2619291573.36
時価総額 時価総額(百万ドル) 2731.168
売上高 売上高(百万ドル) 0.87316
企業価値(EV) 企業価値(EV)(百万ドル) 2326.0657
当期純利益 当期純利益(百万ドル) -151.88880
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Ascendis Pharma A/S revenues decreased 94% to EUR46K. Net loss increased 15% to EUR64.2M. Revenues reflect Revenue from the rendering of services decrease of 90% to EUR46K. Higher net loss reflects Research and development costs - Balance increase from EUR20.8M to EUR66.4M (expense) Stock-based Compensation in General increase from EUR1.2M to EUR4.6M (expense).

 ASNDのテクニカル分析


 ASNDのニュース

   Ascendis Pharma EPS misses by €0.50, misses on revenue (NASDAQ:ASND)  2020/08/27 20:13:33 Seeking Alpha
Ascendis Pharma (NASDAQ:ASND): Q2 GAAP EPS of -€1.97 misses by €0.50. Revenue of €1.44B (-55.1% Y/Y) misses by $720M. Cash equivalents and marketable secur
   Ascendis Pharma TransCon CNP an Orphan Drug in Europe for dwarfism (NASDAQ:ASND)  2020/08/12 18:53:35 Seeking Alpha
The European Commission has designated Orphan Drug status to Ascendis Pharma's (ASND +0.5%) TransCon C-Type Natriuretic Peptide (CNP) for achondroplasia, a
   Global Hypoparathyroidism Pipeline Monitor 2020 with Analysis of 11 Companies Including Ascendis Pharma, Eli Lilly & Co and Takeda Pharma - ResearchAndMarkets.com  2020/08/03 10:50:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Hypoparathyroidism Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering. PIPELINE HIGHLIGHTS Hypoparathyroidism is one of the widely researched conditions during 2020 with 11 companies actively focusing on realizing pipeline's potential. Development of Hypoparathyroidism medicines is identified as integral to the strategy of the majority of compa
   Ascendis Pharma prices ADS offering at $142 (NASDAQ:ASND)  2020/07/08 08:31:26 Seeking Alpha
Ascendis Pharma (NASDAQ:ASND) has priced its public offering of 4,225,352 American Depositary Shares (ADSs), each of which represents one ordinary share, a
   Ascendis Pharma initiates ADSs public offering (NASDAQ:ASND)  2020/07/06 17:08:50 Seeking Alpha
Ascendis Pharma (ASND +1.5%) commenced an underwritten public offering of $500M American Depositary Shares with 30-day underwriters option to purchase up t
   Ascendis Pharma prices ADS offering at $142 (NASDAQ:ASND)  2020/07/08 08:31:26 Seeking Alpha
Ascendis Pharma (NASDAQ:ASND) has priced its public offering of 4,225,352 American Depositary Shares (ADSs), each of which represents one ordinary share, a
   Ascendis Pharma initiates ADSs public offering (NASDAQ:ASND)  2020/07/06 17:08:50 Seeking Alpha
Ascendis Pharma (ASND +1.5%) commenced an underwritten public offering of $500M American Depositary Shares with 30-day underwriters option to purchase up t
   Merit Medical Reaches Deal With Starboard Value  2020/05/30 01:28:00 Barron's
Starboard will take three seats on the board of Merit Medical, a maker of disposable medical devices. Also, Ascendis Pharma and Spectrum Brands see big investors lower stakes.
   The 9 top biotech stocks to buy now to get through the coronavirus crisis, according to JPMorgan  2020/04/03 15:57:00 Business Insider
In an April 3 research note, JPMorgan identified nine biotechnology companies they see as the best investment ideas for 2020. In past recessions, in 2001 and 2008-2009, the biotech industry outperformed the broader market. This time around, JPMorgan sees smaller biotechs facing a few big risks, such as disruptions to clinical trials and tightening liquidity for the capital markets. Here are the bank's top ideas of 2020 in the biotech industry. Visit Business Insider's homepage for more stories . As the coronavirus pandemic roils financial markets, JPMorgan analysts are highlighting the biotechnolgy industry as one space that has outperformed in past recessions. In 2008-2009, a leading biotech index outperformed by gaining 1% while the broader market dropped 23%. And in the 2001 recession, the analysts state that same biotech index held flat while the S&P 500 dropped 9%. This time around, biotech does face some heightened risks. Small companies that depend on clinical trials running on time and launching new drugs could face setbacks , because of the coronavirus overwhelming the healthcare system.
   What's The Path Forward For Ascendis Pharma (ASND)?  2020/03/09 05:28:00 RTT News
Ascendis Pharma A/S (ASND), a clinical-stage biopharmaceutical company focusing on endocrinology rare disease, is all set to report results from a phase II study of TransCon PTH for adult hypoparathyroidism by the end of this month.
   Ascendis Pharma prices ADS offering at $142 (NASDAQ:ASND)  2020/07/08 08:31:26 Seeking Alpha
Ascendis Pharma (NASDAQ:ASND) has priced its public offering of 4,225,352 American Depositary Shares (ADSs), each of which represents one ordinary share, a
   Ascendis Pharma initiates ADSs public offering (NASDAQ:ASND)  2020/07/06 17:08:50 Seeking Alpha
Ascendis Pharma (ASND +1.5%) commenced an underwritten public offering of $500M American Depositary Shares with 30-day underwriters option to purchase up t
   Merit Medical Reaches Deal With Starboard Value  2020/05/30 01:28:00 Barron's
Starboard will take three seats on the board of Merit Medical, a maker of disposable medical devices. Also, Ascendis Pharma and Spectrum Brands see big investors lower stakes.
   The 9 top biotech stocks to buy now to get through the coronavirus crisis, according to JPMorgan  2020/04/03 15:57:00 Business Insider
In an April 3 research note, JPMorgan identified nine biotechnology companies they see as the best investment ideas for 2020. In past recessions, in 2001 and 2008-2009, the biotech industry outperformed the broader market. This time around, JPMorgan sees smaller biotechs facing a few big risks, such as disruptions to clinical trials and tightening liquidity for the capital markets. Here are the bank's top ideas of 2020 in the biotech industry. Visit Business Insider's homepage for more stories . As the coronavirus pandemic roils financial markets, JPMorgan analysts are highlighting the biotechnolgy industry as one space that has outperformed in past recessions. In 2008-2009, a leading biotech index outperformed by gaining 1% while the broader market dropped 23%. And in the 2001 recession, the analysts state that same biotech index held flat while the S&P 500 dropped 9%. This time around, biotech does face some heightened risks. Small companies that depend on clinical trials running on time and launching new drugs could face setbacks , because of the coronavirus overwhelming the healthcare system.
   What's The Path Forward For Ascendis Pharma (ASND)?  2020/03/09 05:28:00 RTT News
Ascendis Pharma A/S (ASND), a clinical-stage biopharmaceutical company focusing on endocrinology rare disease, is all set to report results from a phase II study of TransCon PTH for adult hypoparathyroidism by the end of this month.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アセンディス・ファ―マ ASND Ascendis Pharma A/S)

 twitter  (公式ツイッターやCEOツイッターなど)